Doxortere 10mg Injection

Doxortere 10mg Injection is a allopathy based anticancer medication that is used to treat various cancers including blood cancers (leukemias, lymphomas, multiple myeloma), breast cancer, ovarian cancer, and others like lung, stomach, thyroid, sarcomas, and AIDS-related Kaposi's sarcoma. Doxortere 10mg Injection contains conventional Doxorubicin Hydrochloride that damage DNA and cell membranes leading to cancer cell death.

Like any other chemical based medication, Doxortere 10mg Injection also has certain common side effects. Consult your doctor, if side effects persist for longer period of time.
● Headache
● Cough
● Diarrhea
● Nausea
● Weakness
● Itchy skin or rash
● Shortness of breath
● Decreased appetite
● Infection in the nose or throat
● Fever
● Pain in your muscles, bones, and joints
● Heart problems
● Bone Marrow Supression
● Secondary Leukaemia Risk
● Severe Allergic Reactions

Doxortere 10mg Injection is administered intravenously (In Veins) by a doctor or an experienced nurse. It is advice not to self administer the injection on your own. For personalized dosage ask your doctor about the same. As Dosage is entirely based on the body surface area, type of cancer, its stage as well as patient's overall health.

Doxortere 10mg Injection contains Doxorubicin Hydrochloride that works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication in cancer cells. It also damages DNA and cell membranes leading to cancer cell death.

• Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics, 10(4), 853-858.
• Carvalho, C., Santos, R. X., Cardoso, S., Correia, S., Oliveira, P. J., Santos, M. S., & Moreira, P. I. (2009). Doxorubicin: the good, the bad and the ugly effect. Current medicinal chemistry, 16(25), 3267-3285.
• Cummings, J., Anderson, L., Willmott, N., & Smyth, J. F. (1991). The molecular pharmacology of doxorubicin in vivo. European Journal of Cancer and Clinical Oncology, 27(5), 532-535.
• Tacar, O., Sriamornsak, P., & Dass, C. R. (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of pharmacy and pharmacology, 65(2), 157-170.